证券代码：600332 证券简称：白云山 公告编号：2025-053 广州白云山医药集团股份有限公司 关于子公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）子 公司广州白云山陈李济药厂有限公司（以下简称"陈李济药厂"）收到国 家药品监督管理局（以下简称"国家药监局"）签发的《药品补充申请批 准通知书》。现将有关情况公告如下： 一、药品的基本情况 生产企业：（1）名称：广州白云山陈李济药厂有限公司；（2）地址： 广州市海珠区广州大道南 1688 号 申请内容：变更药品规格 1 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准本品变更药品规格的补充申请，同意 增加小蜜丸规格，规格：每 40 丸重 10g（每 1g 相当于饮片 0.52g），有 效期：24 个月。 药品通用名称：千金保孕丸 剂型：丸剂（小蜜丸） 通知书编号：2025B01053 受理号：CYZB2401460 药品注册标准编号：Y ...

白云山（600332）公告，子公司陈李济药厂收到国家药监局签发的《药品补充申请批准通知书》。药品 通用名称为千金保孕丸，剂型为丸剂(小蜜丸)，通知书编号为2025B01053，受理号为CYZB2401460，药 品注册标准编号为YBZ00162025。原药品批准文号为国药准字Z44022637。申请内容为变更药品规格， 审批结论为批准本品变更药品规格的补充申请，同意增加小蜜丸规格，规格：每40丸重10g(每1g相当于 饮片0.52g)，有效期：24个月。 ...

证券代码：600332 证券简称：白云山 公告编号：2025－052 广州白云山医药集团股份有限公司 关于分公司收到药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白云山制药总厂"）收到国家药品监督管理局核准签发关于盐酸曲 美他嗪缓释片（35mg）的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品通用名称：盐酸曲美他嗪缓释片 剂型：片剂 规格：35mg 注册分类：化学药品 4 类 证书编号：2025S02152 药品注册标准编号：YBH16172025 上市许可持有人：（1）名称：广州白云山医药集团股份有限公 司白云山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 生产企业：（1）名称：广州白云山医药集团股份有限公司白云 山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 受理号：CYHS2400195 药品批准文号：国药准字 H20254831 药 ...

Group 1 - The event "Inheriting Good Family Traditions and Good Family Values" organized by Baiyunshan Xiaochaihu celebrated its 8th anniversary, combining traditional Chinese medicine culture with family values [4][12] - The event took place at the Lingshou City Cultural Square in Jinan, featuring various traditional elements and modern vitality, attracting many local residents [4][16] - The event included family story-sharing sessions, where families shared their unique family values, emphasizing the importance of moral education and daily practice [5][18] Group 2 - Interactive segments such as audience Q&A and dialect games were included, allowing participants to engage and learn about traditional Chinese medicine in a fun atmosphere [9][11] - The event highlighted Baiyunshan Xiaochaihu's commitment to social responsibility through various initiatives, including pandemic donations and cultural inheritance [12][18] - The leaders' speeches during the event called for families to work together to promote good family values and spread positive social energy [16][18]

Core Points - The event "Inheriting Good Ancient Recipes, Inheriting Good Family Traditions" by Baiyunshan Xiaochaihu marks its 8th anniversary and aims to promote positive family values in Shandong [1][2] - The event was live-streamed on social media platforms, achieving over 1.14 million views [2] - Baiyunshan Xiaochaihu has been actively involved in social responsibility initiatives, including donations exceeding 10 million yuan for various causes [7] Group 1 - The event was held in Jinan, Shandong, and is part of a broader initiative to spread love and positive energy through family values [1][2] - Baiyunshan Xiaochaihu has organized this event across 12 provinces over the past eight years, sharing over 200 stories of good family traditions [6][15] - The event featured participation from various local leaders and organizations, highlighting community collaboration [6][21] Group 2 - Baiyunshan Xiaochaihu announced a new initiative called "One More Penny of Care," where a portion of sales will be donated to public welfare projects [16] - The company received a gold award at the 50th Geneva International Exhibition for its innovative Xiaochaihu granules, showcasing its commitment to modernizing traditional medicine [15] - The upgraded national standard for Xiaochaihu granules has been included in the 2025 edition of the Chinese Pharmacopoeia, reflecting industry recognition [15] Group 3 - The event included performances and cultural displays, emphasizing the rich cultural heritage of Shandong [24][27] - Families sharing their good family traditions were recognized, reinforcing the importance of family values in society [20][30] - Baiyunshan Xiaochaihu plans to continue its "Finding Good Family Traditions" initiative to enrich cultural life and promote social virtues [30]

Core Viewpoint - A recent network meta-analysis published in a core journal indicates that Baiyunshan Gushen Dingchuan Wan shows superior efficacy in improving clinical effectiveness and forced vital capacity (FVC) for treating stable chronic obstructive pulmonary disease (COPD) [2][3][9]. Group 1: Research Findings - The study reviewed randomized controlled trials of oral traditional Chinese medicine for stable COPD treatment, utilizing a network meta-analysis approach [6][7]. - Results demonstrated that five types of oral traditional Chinese medicines significantly improved treatment outcomes with a high safety profile and minimal adverse reactions [8][9]. - Among the evaluated medicines, Gushen Dingchuan Wan exhibited the best performance in enhancing clinical effectiveness and FVC [9]. Group 2: Treatment Mechanism - Gushen Dingchuan Wan is formulated based on principles of warming the kidneys and lungs, and strengthening the spleen to alleviate symptoms in COPD patients with kidney and lung qi deficiency [10][13]. - The medicine aims to improve lung function and promote respiratory muscle recovery, thereby enhancing patient vitality and quality of life [11][14]. Group 3: Clinical Guidelines and Recommendations - Gushen Dingchuan Wan is included in several authoritative guidelines and consensus recommendations for COPD treatment, such as the "Clinical Application Guidelines for Integrated Traditional and Western Medicine in COPD (2024)" [16][17]. - Its inclusion in these guidelines supports its further application and promotion in the treatment of related diseases [20].

Core Viewpoint - The 2025 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2025 China will be held on July 4-5, 2025, focusing on significant research findings from the ASCO annual meeting and enhancing the influence of Chinese scholars in the international arena [2]. Group 1: Clinical Research Findings - The IV phase clinical study led by Professor Liu Zhigang on "Baiyunshan Nasopharyngeal Detox Granules" demonstrated significant improvements in severe nasal secretion symptoms and reduced the incidence of severe oral mucositis in nasopharyngeal cancer patients undergoing radiotherapy, indicating a promising innovative treatment option [2]. - The study also reported improvements in symptoms such as throat pain and dryness, showcasing good safety profiles for the treatment [2]. Group 2: Background and Development - Radiotherapy remains the primary curative method for nasopharyngeal cancer, with approximately 90% of patients experiencing adverse reactions like radiation-induced oral mucositis, which severely impacts treatment outcomes and quality of life [3]. - Baiyunshan and Huang Zhong Medicine have invested in clinical research since 2022 to address radiation-induced damage in the nasopharyngeal area, with the project supported by prominent experts in the field [3][4]. - Baiyunshan Nasopharyngeal Detox Granules, developed in collaboration with Sun Yat-sen University Cancer Center and Guangzhou Pharmaceutical Group, is clinically used for chronic inflammation and increased secretion symptoms post-radiotherapy [4].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/ ...

廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易進展公告 向白雲山生物增資 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年5月28日之公告（「該公告」）,內容 有關向白雲山生物增資之關連交易。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵 義。 董事會欣然宣佈於2025年6月30日，本公司與廣藥創投基金、廣州老字號基金、廣藥產投基金、國資 併購基金、拜迪生物及白雲山生物訂立了增資協議，增資協議於同日正式生效。增資協議的主要條 款並無任何變更。增資協議的主要條款及本次增資詳情載於該公告。 本次增資完成後，本公司於白雲山生物的直接及間接持股比例維持不變，仍為50.00%。白雲山生物 仍為本公司之附屬公司，其財務業績繼續納入本公司之合併報表。 中國廣州，2025年6月30日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執 ...

Group 1 - The board of directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. held its 26th meeting of the 9th session on June 23, 2025, with all 9 directors participating and voting [1][2] - The meeting approved the proposal to add new members to the specialized committees of the board, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [1] - The newly appointed members to the specialized committees include Mr. Li Xiaojun, Mr. Cheng Hongjin, and Mr. Tang Heping, effective from the date of the board's approval until the end of the current board's term [1][2] Group 2 - The composition of the Strategic Development and Investment Committee now includes Mr. Li Xiaojun as the chairperson and members Mr. Li Hong, Mr. Chen Yajin, and Ms. Sun Baoqing [1] - The Nomination and Remuneration Committee is chaired by Mr. Huang Min, with members including Mr. Chen Yajin, Ms. Sun Baoqing, and the newly added Mr. Cheng Hongjin [2] - The Budget Committee is chaired by Mr. Chen Yajin, with members including Ms. Cheng Ning, Mr. Huang Min, Mr. Huang Longde, and the newly added Mr. Tang Heping [2]